Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 août 2018 18h00 HE | Source: BeiGene, LTD.

BeiGene Announces Acceptance of its First New Drug Application for Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma by China Drug Administration

BEIJING, China and CAMBRIDGE, Mass., Aug. 26, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
09 août 2018 05h05 HE | Source: BeiGene, LTD.

BeiGene Reports Second Quarter 2018 Financial Results

CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
08 août 2018 16h05 HE | Source: BeiGene, LTD.

BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering

BEIJING, China and CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
02 août 2018 06h44 HE | Source: BeiGene, LTD.

BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering

BEIJING, China and CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
27 juil. 2018 07h08 HE | Source: BeiGene, LTD.

BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering

CAMBRIDGE, Mass. and BEIJING, China, July 27, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
24 juil. 2018 16h30 HE | Source: BeiGene, LTD.

BeiGene Initiates Phase 3 Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in China

BEIJING, China, and CAMBRIDGE, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
24 juil. 2018 07h00 HE | Source: BeiGene, LTD.

BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer

BEIJING, China and CAMBRIDGE, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
22 juil. 2018 16h30 HE | Source: BeiGene, LTD.

百济神州公布PD-1抗体Tislelizumab治疗霍奇金淋巴瘤的关键性试验的初步主要结果

中国北京和美国麻省剑桥, July 23, 2018 (GLOBE NEWSWIRE) -- 百济神州（纳斯达克代码: BGNE），是一家处于商业阶段的生物医药公司，专注于用于癌症治疗的创新型分子靶向和肿瘤免疫药物的开发和商业化。公司今天公布其在研PD-1抗体tislelizumab治疗复发/难治性经典霍奇金淋巴瘤（R/R cHL）中国患者的关键性临床2期试验的独立评审的初步主要结果。 ...
22 juil. 2018 16h30 HE | Source: BeiGene, LTD.

BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma

BEIJING, China and CAMBRIDGE, Mass., July 22, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
22 juil. 2018 16h30 HE | Source: BeiGene, LTD.

百济神州宣布美国FDA授予其BTK抑制剂Zanubrutinib用于治疗华氏巨球蛋白血症患者的快速通道资格

计划于2019年上半年提交美国新药上市申请全球临床3期试验治疗WM完成患者入组美国麻省剑桥和中国北京, July 23, 2018 (GLOBE NEWSWIRE) -- 百济神州（纳斯达克代码:...

Page précédente

Page suivante